Thursday, January 05, 2017 9:28:17 AM
Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time
PRINCETON, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) announced today that its Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2017 on Monday, January 9, 2017 at 9:00 AM Pacific Time. The conference will be held at the Hilton San Francisco Union Square.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile
Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Recent AGRX News
- Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/28/2024 12:05:00 PM
- Agile Therapeutics Announces Delisting from Nasdaq • GlobeNewswire Inc. • 03/25/2024 08:30:00 PM
- Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 10:35:00 AM
- Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 • GlobeNewswire Inc. • 03/20/2024 12:15:00 PM
- Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution • GlobeNewswire Inc. • 03/13/2024 11:31:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 09:57:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 09:55:25 PM
- Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds • GlobeNewswire Inc. • 02/22/2024 02:01:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:30 PM
- Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update • GlobeNewswire Inc. • 02/15/2024 09:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:02:00 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/07/2024 09:51:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:14:35 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/05/2024 02:21:25 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/02/2024 09:27:13 PM
- The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost • GlobeNewswire Inc. • 01/23/2024 02:29:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/20/2023 01:00:42 PM
- Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement • GlobeNewswire Inc. • 12/12/2023 01:01:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/11/2023 10:30:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:00:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:15:21 PM
- Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 01:05:00 PM
- Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023 • GlobeNewswire Inc. • 10/26/2023 12:05:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM